With the aim of protecting more and more Greek patients, a new product in Cardiovascular Medicine is launched. KERENDIA is now available for patients with CKD & Type 2 Diabetes. Welcome to Bayer Hellas internal Kerendia launch event, focusing on educating & preparing the Sales Team for a successful product promotion in the Greek market. In this event, you familiarized yourselves with the promotional materials & the role plays. This is the first POAP related to a pharmaceutical product. If you received this POAP, you are a True Pioneer in the Web3 space. Bayer is proudly promoting innovative practices. https://www.bayer.com/en/poap-tc

Systems Manager based in London, UK. Currently supporting IMPACT (Clinical Trials Management System), CART (Spotfire reporting) and Gemstone (Veeva). Previous experience with reporting support in Business Objects and Microstrategy. Have been working at Bayer since 2006. Degree in BSc Computer Science.

You have been part of our Bayer R&D Buffet in November, where we have focused on every aspect of our TNN implementation. The food for thought was delicious, the outlook was bright, and our journey together as ONE R&D looks promising! Thank you for being part of our team that helps pathing the way for an inclusive and innovative workspace. Website: https://www.bayer.com/

Rolf, at the Madrid meeting 2023. Soccer player and beer afficionado, father of three kids in puberty

ChemogenomicsDB (CGDB) and Älixir are prime examples of creating data assets and insight solutions to help improve digital and data capabilities, enhance scientific productivity, and invigorate early pipeline. Using our products, Bayer R&D colleagues can - access to a broad range of data assets essential for solving key drug discovery questions - explore integrated biomedical and chemical data for scientific curiosity, inspiration, and knowledge discovery - generate insights with the assistance of interactive visualizations for evidence-informed decision making